Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 24, 2022 10:47am
131 Views
Post# 34541282

RE:Now it's embarassing really

RE:Now it's embarassing reallyIt  is hard to disagree with your assessment. As best I can tell, these are all nice people at TH who are trying to do a good job for shareholders but I am not even sure they are even fully willing to acknowledge they have that five alarm fire that I have used as a way of describing it on their hands. We have a mindless seller crushing the share price right now despite what certainly looks like imminent good news on the immediate horizon. But had TH done an even adequate job of creating a favorable narrative around the stock, attracting decent analysts to cover it and forging a positive relationship with the capital markets generally, then there would be buyers to soak up this sellers shares. But they didn't and we are paying the price for that. We likely will not be paying it for long as the seller will run out of shares to sell soon enough, but it really highlights the company's failures in the capital markets arena. It is unfortunate since they do have some very interesting things going on in cancer and maybe even in NASH at some point.  

You may remember a similiar nasty sell-off in the  Fall of 2018 if I recall correctly when a new mutual fund manager took over a fund with Th in it and sold it as fast as he could because  he wanted to own the stocks he was familiar with. It is a nasty thing but when sommething like this happens it usually doesn't last too long. 

Trogarzon wrote:
To Th management and board this is directed at you. You are a shameful embarassement to your shareholder for the situation that we find ourselves in regardless of your revenu basis and pipeline potential. You are an embarassement.


<< Previous
Bullboard Posts
Next >>